People, you're missing the message !!! Ve vant
Post# of 30066
Posted On: 01/10/2015 10:22:13 AM
People, you're missing the message !!!
Ve vant ze money, Lebowski !!!
It's time to pump and put unrealistic expectations on GC and the company now !!!(again). So, do it or get "run down" for not being open mined and seeing it their way! Cause obviously their way has proven to be right...or at least worked for the trade...
The crew is back.
AMBS WILL sell LymPro soon!
numbers WILL be in the high 90's!
GC WILL tell us about revenue
GC just might regain some "Cred" after losing it entirely
It's time. This next week it's make or break for the company!
Or maybe they WILL
Present an overview of its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of Retinitis Pigmentosa (RP) and Retinal Artery Occlusion (RAO) and its Phase 2b-ready small molecule drug candidate Eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD LID) and Adult ADHD.
Present a corporate overview including top-line results of its expanded LP-002 study of the Lymphocyte Proliferation Test (LymPro Test®) blood diagnostic for Alzheimer's disease (AD)
Ok, who's the funny guy that included "small molecule" in the PR?! Not funny !!!
GL luck with reading and dealing with them. But some of us ask, if you reply, can some of it be By PM, cause this is going to get so redundant ....again....
Cheers
Ve vant ze money, Lebowski !!!
It's time to pump and put unrealistic expectations on GC and the company now !!!(again). So, do it or get "run down" for not being open mined and seeing it their way! Cause obviously their way has proven to be right...or at least worked for the trade...
The crew is back.
AMBS WILL sell LymPro soon!
numbers WILL be in the high 90's!
GC WILL tell us about revenue
GC just might regain some "Cred" after losing it entirely
It's time. This next week it's make or break for the company!
Or maybe they WILL
Present an overview of its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of Retinitis Pigmentosa (RP) and Retinal Artery Occlusion (RAO) and its Phase 2b-ready small molecule drug candidate Eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD LID) and Adult ADHD.
Present a corporate overview including top-line results of its expanded LP-002 study of the Lymphocyte Proliferation Test (LymPro Test®) blood diagnostic for Alzheimer's disease (AD)
Ok, who's the funny guy that included "small molecule" in the PR?! Not funny !!!
GL luck with reading and dealing with them. But some of us ask, if you reply, can some of it be By PM, cause this is going to get so redundant ....again....
Cheers
(0)
(0)